S. 4189 · 119th Congress · Health

INSULIN Act of 2026

Unknown; bill summary not yet available. AI-read

Out of committee11k words Introduced Mar 25, 2026 · Latest action Aug 7, 2026

How far it has goneStage 3 of 6
  1. IntroducedMar 25, 2026 Done
  2. CommitteeReported Aug 7, 2026 Done
  3. Senate floorAwaiting vote Current stage
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.

Who lobbies on it

10 organizations, more than 96% of Senate bills · 14 filings · Q1 2026–Q3 2026

These 10 organizations’ PACs gave $86.1K to 13 of the 29 members sponsoring or cosponsoring S. 4189 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the Senate → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. America's Health Insurance Plans Inc (ahip) 2 of 3 quarters
    “…S. 4189 - INSULIN Act - Sen. Collins, Susan - Insulin cost-sharing caps S. 4512 - Affordable Insulin Now Act - Sen. Kennedy, John - Insulin cost-sharing caps Issues related to implementation rule implementing the No Surprises Act prohibiting surprise medical bills; transparency report requirements; parity in mental…”

    $11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Pharmaceutical Care Management Association 2 of 3 quarters
    “…Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570…”

    $9.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Highmark Inc 2 of 3 quarters
    “PBM Reform, transparency S. 1414, Expedited Access to Biosimilars Act - A bill to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. S.4189 - INSULIN Act of 2026…”

    $780K lobbying spend in 2026 to date, all issuesQ3 2026 filing

7 more organizations, every filingPROUpgrade

Organizations that named S. 4189 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

5 actions · newest first
  1. Aug 7, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 552.
  2. Aug 7, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
  3. Jul 22, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. Mar 25, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Show all 5 actionsShow fewer
  1. Mar 25, 2026Introduced in Senate

What members said about it

  • Statement · Press release · Jun 11, 2026 · Hyde-Smith R-MS

    HYDE-SMITH COSPONSORS BIPARTISAN LEGISLATION TO CAP OUT-OF-POCKET INSULIN COSTS

    Pocket Cost at $35, Reinforce Patient Protections WASHINGTON, D.C. – U.S. Senator Cindy Hyde-Smith (R-Miss.) on Tuesday agreed to cosponsor bipartisan legislation to lower the cost of insulin, reinforce patient protections, and make the…

    “The INSULIN Act represents a strong, bipartisan effort to try to stop the unnecessary year-over-year increase in the price of insulin. Mississippians from across the state share their stories of their stress caused by insulin prices.”
  • Statement · Press release · Jun 11, 2026 · Hyde-Smith R-MS

    INSULIN Act would limit out-of-pocket costs to $35 monthly

    Legislation now in the U.S. Senate would lower the cost of insulin for patients with diabetes, as well as reinforce patient protections.

    “The INSULIN Act represents a strong, bipartisan effort to try to stop the unnecessary year-over-year increase in the price of insulin. Mississippians from across the state share their stories of their stress caused by insulin prices.”